Global ACTH Deficiency Market Size, Share and Trends Analysis Report – Industry Overview and Forecast to 2032

ACTH Deficiency Market Size

• The global ACTH deficiency market size was valued at USD 500.50 million in 2024 and is expected to reach USD 859.95 million by 2032, at a CAGR of 7.00% during the forecast period
• The market growth is largely fueled by increasing prevalence of ACTH deficiency, advancements in diagnostic techniques, and development of effective treatment options, leading to improved patient outcomes in both hospital and clinical settings
• Furthermore, rising awareness among healthcare professionals and patients, along with better access to healthcare services, is establishing ACTH deficiency treatments as the preferred therapy, accelerating the uptake of treatment solutions and significantly boosting the industry's growth

ACTH Deficiency Market Analysis

• ACTH deficiency treatments, addressing the insufficient production of adrenocorticotropic hormone, are increasingly vital components of endocrine disorder management in both hospital and clinical settings due to their effectiveness in regulating cortisol levels, preventing adrenal crises, and improving patient quality of life
• The escalating demand for ACTH deficiency treatments is primarily fueled by the growing prevalence of ACTH deficiency, advancements in diagnostic techniques enabling early detection, and a rising preference for personalized and effective hormone replacement therapies
• North America dominated the ACTH deficiency market with the largest revenue share of 38.2% in 2024, characterized by advanced healthcare infrastructure, high awareness among healthcare professionals, and a strong presence of key pharmaceutical players, with the U.S. experiencing substantial growth in treatment adoption, particularly in specialized endocrine clinics and hospitals, driven by innovations in long-acting formulations and combination therapies
• Asia-Pacific is expected to be the fastest growing region in the ACTH deficiency market during the forecast period due to increasing healthcare access, rising awareness about endocrine disorders, and expanding availability of treatment options
• Secondary adrenal insufficiency segment dominated the ACTH deficiency market with a market share of 42.8% in 2024, driven by its higher prevalence among patients, well-established diagnostic protocols, and the availability of effective hormone replacement therapies

Report Scope and ACTH Deficiency Market Segmentation    

ACTH Deficiency Market Trends

Personalized Hormone Replacement Therapies

• A significant and accelerating trend in the global ACTH deficiency market is the shift towards personalized hormone replacement therapies tailored to patient-specific needs, improving treatment efficacy and quality of life
  • For instance, new long-acting ACTH formulations allow individualized dosing schedules, reducing the frequency of injections and minimizing side effects
• Advances in diagnostic tools, including AI-assisted cortisol monitoring, enable more precise treatment adjustments, improving patient outcomes and adherence
• Personalized treatment approaches also facilitate better management of comorbidities associated with ACTH deficiency, such as adrenal insufficiency and secondary endocrine disorders
• This trend is driving pharmaceutical companies such as Pfizer and Novartis to invest in tailored ACTH therapy programs with digital monitoring and patient-centric support
• The demand for customized hormone replacement therapies is growing rapidly across both hospital and specialty clinic settings as patients and physicians prioritize treatment efficacy and convenience
• Increasing integration of digital health solutions, including telemedicine consultations and remote monitoring of cortisol levels, is enhancing treatment accessibility and continuous care
• Collaborative research between biotech firms and academic institutions is accelerating the development of next-generation ACTH therapies with improved safety profiles and targeted delivery systems

ACTH Deficiency Market Dynamics

Driver

Rising Prevalence of ACTH Deficiency and Awareness

• The increasing prevalence of ACTH deficiency worldwide, coupled with heightened awareness among healthcare professionals and patients, is a significant driver for market growth
  • For instance, diagnostic centers in North America and Europe have reported higher rates of secondary adrenal insufficiency, boosting treatment adoption
• As more patients are diagnosed early, demand for effective hormone replacement therapies increases, supporting market expansion
• Growing awareness campaigns and medical education programs are enabling timely detection and management, enhancing treatment uptake
• Physicians’ preference for clinically validated therapies and increasing healthcare access are further propelling market growth in both developed and emerging regions
• Expansion of healthcare insurance coverage for hormone replacement therapies is encouraging more patients to seek treatment, increasing overall market penetration
• Government initiatives to improve endocrine disorder management, including funding for specialized clinics and patient assistance programs, are further supporting market growth

Restraint/Challenge

Treatment Side Effects and Limited Access in Emerging Regions

• Potential side effects of hormone replacement therapy, including electrolyte imbalance and overexposure to corticosteroids, pose a significant challenge to wider adoption of ACTH deficiency treatments
  • For instance, some patients experience complications from improper dosing, creating hesitancy among new users and physicians
• Limited healthcare infrastructure and treatment availability in emerging regions restrict access, constraining market growth in Asia-Pacific and Africa
• The high cost of some advanced ACTH therapies further limits adoption among price-sensitive populations, particularly in low-income countries
• Overcoming these challenges through improved dosing protocols, patient monitoring, and expansion of treatment access will be vital for sustained market growth
• Lack of standardized treatment guidelines in some regions can result in inconsistent patient care and slower market adoption
• Challenges in patient adherence to long-term therapy regimens, due to frequent monitoring or complex dosing schedules, may hinder consistent market growth

ACTH Deficiency Market Scope

The market is segmented on the basis of type, management, related disorders, end users, and distribution channels.

• By Type

On the basis of type, the ACTH deficiency market is segmented into acquired and congenital. The acquired segment dominated the market with the largest revenue share of 57% in 2024, driven by the higher prevalence of secondary adrenal insufficiency caused by pituitary disorders, infections, or long-term steroid use. Acquired ACTH deficiency is more frequently diagnosed in adults, leading to higher treatment adoption in hospital and specialty clinic settings. Early diagnosis and access to effective hormone replacement therapies further support the dominance of this segment. Healthcare providers often prioritize acquired cases for intervention due to the immediate risk of adrenal crises and long-term complications. The availability of established treatment protocols and broader clinical awareness contributes significantly to market leadership. In addition, pharmaceutical companies focus on developing targeted therapies and patient support programs for acquired ACTH deficiency, enhancing market growth.

The congenital segment is anticipated to witness the fastest growth rate of 9.2% from 2025 to 2032, fueled by increasing awareness and improved diagnostic capabilities for rare pediatric endocrine disorders. Early screening and neonatal testing for congenital ACTH deficiency allow timely initiation of treatment, preventing severe complications and improving patient quality of life. Advances in genetic testing and personalized medicine are further boosting treatment adoption in pediatric populations. Increased investment in pediatric endocrinology clinics and collaborations with healthcare institutions support the segment’s rapid expansion. Parents and caregivers increasingly seek specialized care, driving demand for innovative therapeutic options. The rising prevalence of congenital adrenal hyperplasia (CAH) and other genetic disorders contributes to this segment’s strong growth trajectory.

• By Management

On the basis of management, the market is segmented into diagnosis and treatment. The treatment segment dominated the market with the largest revenue share of 62% in 2024, driven by the widespread adoption of corticosteroid replacement therapies and long-acting ACTH formulations. Treatments are essential for preventing adrenal crises and regulating cortisol levels in diagnosed patients. Hospitals and specialty clinics prefer treatment interventions due to their immediate impact on patient health and long-term disease management. Pharmaceutical advancements, including personalized dosing and combination therapies, are further supporting market leadership. Increasing awareness among healthcare professionals about effective treatment protocols also drives adoption. The treatment segment benefits from reimbursement programs and insurance coverage in developed regions, enhancing its market share.

The diagnosis segment is expected to witness the fastest growth rate of 10.1% from 2025 to 2032, fueled by advances in diagnostic technologies such as AI-assisted cortisol monitoring, genetic testing, and imaging tools. Early and accurate diagnosis allows timely initiation of therapy, preventing severe complications and improving patient outcomes. The rising focus on screening programs for high-risk populations is boosting market growth. Integration of digital health platforms enables remote monitoring and early detection, driving adoption in both hospital and specialty clinic settings. Increased government initiatives and healthcare awareness campaigns are promoting early diagnosis. The segment’s expansion is further supported by collaborations between diagnostic labs and endocrine clinics to streamline patient care.

• By Related Disorders

On the basis of related disorders, the market is segmented into congenital adrenal hyperplasia (CAH), Addison’s disease, secondary adrenal insufficiency, Sheehan’s syndrome, and others. The secondary adrenal insufficiency segment dominated the market with a revenue share of 42.8% in 2024, driven by its higher prevalence in adults due to pituitary or hypothalamic dysfunction. Secondary adrenal insufficiency often requires immediate treatment to prevent life-threatening adrenal crises. Established diagnostic protocols and effective hormone replacement therapies contribute to the segment’s dominance. Awareness among endocrinologists and hospital protocols support early detection and treatment adoption. The segment benefits from ongoing clinical research and new formulation development for more convenient dosing. Patient education programs also increase adherence to therapy, further boosting market leadership.

The CAH segment is expected to witness the fastest growth rate of 11.4% from 2025 to 2032, fueled by increasing newborn screening programs and growing awareness about congenital disorders. Early detection of CAH allows timely initiation of corticosteroid therapy, improving long-term outcomes for pediatric patients. Advances in genetic testing and personalized treatment plans are contributing to higher adoption rates. Collaboration between pediatric endocrinologists and specialty clinics enhances treatment accessibility. Patient advocacy and awareness campaigns are further driving market growth. The increasing prevalence of rare congenital disorders globally supports rapid expansion of this segment.

• By End Users

On the basis of end users, the market is segmented into hospitals, specialty clinics, and others. The hospitals segment dominated the market with a revenue share of 47.2% in 2024, driven by access to advanced diagnostic and treatment facilities and higher patient trust in hospital-administered therapies. Hospitals often manage severe or complex cases requiring immediate intervention, boosting treatment uptake. Experienced endocrinologists and multidisciplinary care teams further support hospital dominance. Availability of long-acting ACTH formulations and inpatient monitoring enhances adoption. Reimbursement policies in hospitals also favor this segment. Hospitals frequently collaborate with pharmaceutical companies for patient assistance programs, strengthening market leadership.

The specialty clinics segment is expected to witness the fastest growth rate of 12.1% from 2025 to 2032, fueled by the increasing number of endocrine and pediatric clinics providing focused care for ACTH deficiency. Specialized care ensures personalized treatment, improved patient adherence, and better management of comorbidities. The expansion of outpatient services and telemedicine integration enhances accessibility. Patients prefer clinics for routine monitoring and follow-ups, driving demand. Collaborations with diagnostic labs and genetic testing centers support early detection. Rising awareness among patients and caregivers about specialized care options is further boosting segment growth.

• By Distribution Channel

On the basis of distribution channels, the market is segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy, and others. The hospital pharmacy segment dominated the market with the largest revenue share of 50% in 2024, driven by its direct access to patients requiring immediate hormone replacement therapy. Hospitals ensure proper dispensing, dosing, and patient counseling, enhancing safety and adherence. The segment benefits from integrated supply chains and established procurement systems. Partnerships with pharmaceutical manufacturers ensure availability of both standard and advanced formulations. Hospital pharmacies are preferred for complex or high-risk cases, boosting revenue share. Reimbursement and insurance support further strengthen hospital pharmacy dominance.

The online pharmacy segment is expected to witness the fastest growth rate of 15.2% from 2025 to 2032, fueled by increasing adoption of e-pharmacy platforms for home delivery of hormone replacement therapies. Convenience, privacy, and access to a wide range of medications drive consumer preference. Integration with telemedicine platforms enables seamless prescription management. Online pharmacies also support patient adherence with reminders and refill services. Expansion of e-commerce infrastructure and digital payment options enhance accessibility in remote areas. Rising consumer confidence in online healthcare services further accelerates segment growth.

ACTH Deficiency Market Regional Analysis

• North America dominated the ACTH deficiency market with the largest revenue share of 38.2% in 2024, characterized by advanced healthcare infrastructure, high awareness among healthcare professionals, and a strong presence of key pharmaceutical players
• Patients and physicians in the region highly value timely diagnosis, effective hormone replacement therapies, and personalized treatment approaches for managing ACTH deficiency and related adrenal disorders
• This widespread adoption is further supported by robust healthcare insurance coverage, strong presence of key pharmaceutical players, and ongoing research and development initiatives, establishing ACTH deficiency treatments as the preferred solution in both hospital and specialty clinic settings

U.S. ACTH Deficiency Market Insight

The U.S. ACTH deficiency market captured the largest revenue share of 82% in 2024 within North America, fueled by advanced healthcare infrastructure, high patient awareness, and widespread availability of specialized endocrine clinics. Patients are increasingly prioritizing timely diagnosis and effective hormone replacement therapies to manage adrenal insufficiency and related disorders. The growing adoption of personalized treatment plans, combined with robust insurance coverage and patient support programs, further propels the ACTH deficiency market. Moreover, ongoing research and development initiatives, including novel long-acting ACTH formulations and digital health monitoring, are significantly contributing to the market's expansion.

Europe ACTH Deficiency Market Insight

The Europe ACTH deficiency market is projected to expand at a substantial CAGR throughout the forecast period, primarily driven by increasing awareness of adrenal disorders and the growing need for early diagnosis and effective management. The rise in urbanization and enhanced healthcare infrastructure is fostering the adoption of advanced hormone replacement therapies. European patients and physicians are also drawn to the convenience and efficacy of personalized ACTH therapies. The region is experiencing significant growth across hospitals and specialty clinics, with treatments being incorporated into both routine care and specialized endocrine programs.

U.K. ACTH Deficiency Market Insight

The U.K. ACTH deficiency market is anticipated to grow at a noteworthy CAGR during the forecast period, driven by rising awareness of adrenal insufficiency and a growing focus on endocrine health. In addition, concerns regarding adrenal crises and long-term complications are encouraging both patients and healthcare providers to seek timely interventions. The U.K.’s adoption of digital health solutions and telemedicine platforms, alongside its robust healthcare system and insurance coverage, is expected to continue stimulating market growth.

Germany ACTH Deficiency Market Insight

The Germany ACTH deficiency market is expected to expand at a considerable CAGR during the forecast period, fueled by increasing awareness of endocrine disorders and a strong emphasis on personalized, evidence-based treatment approaches. Germany’s well-developed healthcare infrastructure, combined with its focus on research and innovation, promotes the adoption of ACTH deficiency treatments, particularly in hospital and specialty clinic settings. Integration of advanced diagnostic tools and long-acting hormone therapies is also becoming increasingly prevalent, with a strong preference for patient-centric, effective management solutions.

Asia-Pacific ACTH Deficiency Market Insight

The Asia-Pacific ACTH deficiency market is poised to grow at the fastest CAGR of 12% during the forecast period of 2025 to 2032, driven by increasing healthcare access, rising awareness of adrenal disorders, and technological advancements in countries such as China, Japan, and India. The region's growing focus on early diagnosis and treatment, supported by government initiatives promoting endocrine health, is driving the adoption of ACTH therapies. Furthermore, as APAC expands its healthcare infrastructure and increases availability of specialty clinics, the accessibility and affordability of ACTH deficiency treatments are improving across a wider patient population.

Japan ACTH Deficiency Market Insight

The Japan ACTH deficiency market is gaining momentum due to the country’s advanced healthcare system, high patient awareness, and demand for convenient, effective treatment options. The Japanese market places a significant emphasis on early diagnosis and personalized therapy, and the adoption of ACTH deficiency treatments is driven by the increasing number of specialty endocrine clinics and hospital programs. Integration of digital monitoring tools and patient support services is fueling growth. Moreover, Japan's aging population is such asly to spur demand for tailored, easy-to-administer hormone replacement therapies in both adult and pediatric populations.

India ACTH Deficiency Market Insight

The India ACTH deficiency market accounted for the largest market revenue share in Asia-Pacific in 2024, attributed to the country's expanding middle class, improving healthcare infrastructure, and rising awareness of adrenal disorders. India stands as one of the fastest-growing markets for endocrine therapies, and ACTH deficiency treatments are becoming increasingly adopted in hospitals, specialty clinics, and outpatient settings. The push towards digital health solutions, increased availability of affordable therapies, and support from domestic and international pharmaceutical companies are key factors propelling the market in India.

ACTH Deficiency Market Share

The ACTH Deficiency industry is primarily led by well-established companies, including:

• Neurocrine Biosciences, Inc. (U.S.)
• Crinetics Pharmaceuticals, Inc. (U.S.)
• Aspect Biosystems Ltd. (Canada)
• AstraZeneca (U.K.)
• Novartis AG (Switzerland)
• Pfizer Inc. (U.S.)
• Eli Lilly and Company (U.S.)
• Sanofi (France)
• Bristol-Myers Squibb Company (U.S.)
• AbbVie Inc. (U.S.)
• Merck & Co., Inc. (U.S.)
• Horizon Therapeutics plc (Ireland)
• Ipsen S.A. (France)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Amgen Inc. (U.S.)
• Bayer AG (Germany)
• Johnson & Johnson Services Inc. (U.S.)
• GSK plc (U.K.)
• Novo Nordisk A/S (Denmark)

What are the Recent Developments in Global ACTH Deficiency Market?

• In September 2025, AstraZeneca initiated a randomized, double-blind, placebo-controlled Phase 2 study to evaluate the effect of Baxdrostat on cortisol reserve in response to an ACTH stimulation test. The study aims to assess Baxdrostat's potential in managing conditions related to cortisol production, such as secondary adrenal insufficiency
• In July 2025, At the Endocrine Society’s annual meeting, Aspect Biosystems presented preclinical data on their adrenal Bioprinted Tissue Therapeutics. These implantable cell therapies aim to restore adrenal function in patients with primary adrenal insufficiency, potentially offering a functional cure for conditions such as Addison's disease and congenital adrenal hyperplasia
• In December 2024, Neurocrine Biosciences received FDA approval for Crenessity (formerly crinecerfont), the first new treatment for congenital adrenal hyperplasia (CAH) in decades. This oral medication targets the underlying hormonal imbalance in CAH patients, offering an alternative to long-term glucocorticoid use. The approval marks a significant milestone in adrenal disorder treatment
• In June 2024, Crinetics Pharmaceuticals reported positive initial findings for Atumelnant in two ongoing open-label studies at ENDO 2024. The studies focus on the treatment of congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing’s syndrome. Atumelnant demonstrated efficacy in reducing adrenal androgen levels, indicating its potential as a therapeutic option for these conditions
• In March 2023, A study published utilized an immunoassay with monoclonal antibodies to detect cortisol levels during the ACTH stimulation test. The research established a cutoff for test failure at a cortisol value ≤ 16.3 μg/dL at 30 minutes post-injection of corticotropin analog, enhancing diagnostic accuracy for secondary adrenal insufficiency

SKU-60793